Home > Insider Trading > Filing (0000905718-18-000995)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1484565	Soleno Therapeutics Inc	SLNO	Electromedical & Electrotherapeutic Apparatus (3845)	770523891

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1762451	Andrew Sinclair	C/O Soleno Therapeutics Inc. 1235 Radio Road, Suite 110 Redwood City CA 94065		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-12-21	4,669,272	$1.60	4,669,272	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock $.001 Par Value	Warrant	Acquisiton	2018-12-21	4,669,272	$0.01	233,463	$2.00
Common Stock $.001 Par Value	Stock Option (right to buy)	Acquisiton	2018-12-21	20,000	$0.00	20,000	$1.57

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,669,272	2018-12-21	2023-12-21	No	4	P	Indirect
20,000		2028-12-21	No	4	A	Direct

Footnotes

Shares are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.
An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
This option was granted on December 21, 2018 with respect to 20,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on December 21, 2018.